Robert W. Baird Has Lowered Expectations for Medpace (NASDAQ:MEDP) Stock Price

Medpace (NASDAQ:MEDP) had its target price reduced by equities researchers at Robert W. Baird from $565.00 to $477.00 in a report released on Friday, MarketBeat.com reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s target price would indicate a potential upside of 16.19% from the company’s previous close.

MEDP has been the topic of a number of other reports. Mizuho set a $582.00 price target on Medpace in a report on Wednesday, February 11th. TD Cowen upgraded Medpace from a “sell” rating to a “hold” rating and dropped their target price for the stock from $462.00 to $419.00 in a research note on Wednesday, February 18th. Weiss Ratings downgraded Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Finally, Barclays dropped their target price on Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Friday. Four research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Medpace currently has an average rating of “Hold” and an average target price of $467.08.

Medpace Trading Up 4.4%

Shares of NASDAQ:MEDP opened at $410.54 on Friday. Medpace has a 12-month low of $284.10 and a 12-month high of $628.92. The business’s fifty day simple moving average is $470.61 and its 200-day simple moving average is $535.75. The company has a market capitalization of $11.73 billion, a PE ratio of 25.80, a P/E/G ratio of 1.85 and a beta of 1.39.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The business had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. During the same period last year, the business posted $3.67 EPS. The business’s revenue was up 26.5% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Research analysts predict that Medpace will post 17.05 EPS for the current year.

Insiders Place Their Bets

In related news, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the transaction, the president directly owned 15,000 shares in the company, valued at $6,829,500. The trade was a 67.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 20.50% of the stock is currently owned by company insiders.

Institutional Trading of Medpace

Several large investors have recently added to or reduced their stakes in the company. Root Financial Partners LLC grew its stake in Medpace by 34.1% during the 1st quarter. Root Financial Partners LLC now owns 122 shares of the company’s stock valued at $59,000 after purchasing an additional 31 shares during the last quarter. Impact Partnership Wealth LLC grew its stake in Medpace by 46.9% during the 1st quarter. Impact Partnership Wealth LLC now owns 1,426 shares of the company’s stock valued at $685,000 after purchasing an additional 455 shares during the last quarter. Brown Miller Wealth Management LLC grew its stake in Medpace by 8.2% during the 1st quarter. Brown Miller Wealth Management LLC now owns 741 shares of the company’s stock valued at $356,000 after purchasing an additional 56 shares during the last quarter. 3Chopt Investment Partners LLC purchased a new stake in Medpace during the 1st quarter valued at about $310,000. Finally, Apollon Wealth Management LLC purchased a new stake in Medpace during the 1st quarter valued at about $259,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Q1 beat and raised outlook — Medpace reported Q1 EPS of $4.28 and revenue of $706.6M, both above consensus, and gave FY2026 EPS guidance of $16.68–$17.50. Strong revenue growth and guidance are the primary bullish catalyst. Article Title
• Positive Sentiment: Analyst support remains — Robert W. Baird kept an Outperform rating with a $477 target (still implying upside), providing some analyst backing despite volatility. Article Title
• Positive Sentiment: Technical/buy‑the‑dip narratives — Some outlets note MEDP moved into oversold territory after recent selling, which can attract short‑term bargain hunters. Article Title
• Neutral Sentiment: Short‑interest data unclear — April short‑interest reporting shows effectively 0 days to cover based on the provided figure, an anomalous data point that appears neutral until clarified by exchanges/brokers.
• Neutral Sentiment: Backlog conversion but rising cancellations — Management highlighted roughly $1.94B of backlog conversion over 12 months, but cancellation rates have increased; this is a mixed operational signal that could either load revenue or indicate instability in bookings. Article Title
• Negative Sentiment: Multiple securities‑fraud class action notices filed and law‑firm solicitations — Several firms have announced lawsuits and are soliciting lead‑plaintiff motions with a June 8, 2026 deadline, increasing legal and investor‑sentiment risk. This is a material near‑term overhang. Article Title
• Negative Sentiment: Analyst caution and downgrades tied to cancellations/elevated costs — Some analysts cut stance or reduced price targets citing the spike in backlog cancellations and higher direct costs (e.g., Seeking Alpha coverage and a BMO price‑target cut to $400), which can pressure sentiment and valuation. Article Title
• Negative Sentiment: Executive departure — Medpace’s president announced his resignation after 18 years, adding leadership transition risk at a sensitive time. Article Title

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.